PREFERABLE_II

#HorizonEU funded project on Personalised Exercise-Oncology for improvement of supportive cancer care

[Anne May @annemariamay]

🙏 to @Europadonna for participating in @preferable_mbc & representing the patients' perspective. It was a pleasure working and continue working with you.
I also thank the European Commissioner @SKyriakidesEU for her video message on PREFERABLE's results: https://t.co/pid3OI16F3

[PREFERABLE_II @PREFERABLE_II]

The PREFERABLE II Consortium was well represented during the #ISEO pre-conference at #ACSM24. @annemariamay presented the PREFERABLE studies as example of successful multinational exercise oncology RCTs, showing that teamwork makes the dream work.

[Moritz Schumann @Moritz_Schumann]

A great morning in Boston at the planning meeting of the International Society of Exercise Oncology #ISEO. Also great to see @annemariamay presenting the preferable consortium as an excellent example for multi center international trials. @PREFERABLE_MBC @PREFERABLE_II

[PREFERABLE_II @PREFERABLE_II]

The @PREFERABLE_II LION RCT has started! The 1st participants @UMCUtrecht & @NKI_nl have signed consent. Thanks @Lifemaxx for sending & sponsoring training materials!
LION investigates effects of life remote exercise for patients after cancer treatment
https://t.co/zzSZOdFXFo

[PREFERABLE_II @PREFERABLE_II]

During our 4th consortium meeting in Stockholm, we discussed the progression of our clinical trial (LION-RCT), survey and focus groups (LION-COM and ELSI) at each site. We are happy to announce that the first center (UMCU) has started inclusions for the clinical trial! #HorizonEU

[PREFERABLE_II @PREFERABLE_II]

Testing the base module of the LION exercise program with the PREFERABLE II team. We are almost ready to start recruitment! @HorizonEU @EUScienceInnov @CanRehab @EvelynMonnin @JanaMue11er

[PREFERABLE_II @PREFERABLE_II]

Informing all Dutch oncologists about the positive effects of exercise as strategy to prevent cancer, improve prognosis & reduce side effects during and after treatment & the LION study, which is about to start recruitment. @annemariamay @AnoukHiensch @HorizonEU #oncologiedagen

[PREFERABLE_II @PREFERABLE_II]

🗣️Ben jij afgelopen jaar behandeld voor kanker en heb je interesse in deelname aan een focusgroep? Ga in gesprek over online beweegprogramma’s na de behandeling van kanker. Interesse? Meer informatie en aanmelden kan hier: https://t.co/yGzPssxtvj
@NFKkanker @borstkanker @hetAVL

[PREFERABLE_II @PREFERABLE_II]

Congrats to our @PREFERABLE_II colleagues for these promising findings! @AJ_Alves @AndreiaCapela1
Cardio-Oncology Rehabilitation for Cancer Survivors With High Cardiovascular Risk https://t.co/Q7bBH5T5wg

[Anne May @annemariamay]

I couldn't do this w/o the fantastic PREF-II women
@canrehab @LyubenovaAn @EvaZopf @JanaMueller11er @SteindorfKaren @Mireia_Paleaz
@AnoukHiensch @ElskenvdWall @ClaussDorothea @HHeleneru @depenbusch_j @kgapo @lvdpollfranse @renskealtena @tweetpoorna @DrWengstrom @AndreiaCapela1

[PREFERABLE_II @PREFERABLE_II]

Nice to meet the @MyPath_EU colleagues in Edinburgh and discuss their project. MyPath is led by @KaasaStein and Marie Fallon👇. MyPath aims to implement patient-centred care pathways in a digital solution for patients with cancer. Working together in the #QoL_Cluster @EU_HaDEA

[PREFERABLE_II @PREFERABLE_II]

Great to discuss the PREFERABLE II live-remote exercise program with our advisor @winters_stone today. Thank you! The program will be evaluated in the LION RCT starting Q1 2024. #HorizonEU @EU_HaDEA #ExerciseOncology

[PREFERABLE_II @PREFERABLE_II]

The PREFERABLE-II consortium met in Hannover 7-8 Sept. We are now finalizing the protocol for the clinical trial (LION-RCT), survey and focus groups (LION-COM and ELSI). Also legal and ethical aspects of live-remote training were discussed. #HorizonEU

[Rob Newton @ProfRobNewton]

Just published by our team at @EMRI_ECU led by @BrendanCrosby27 co-authored with @Pedro_Lopez1291 @tmeniawy @DrWeis_oncology @ElinSGrayPhD @favil_singh
An 8-week telehealth exercise intervention is feasible and safe for patients with advanced melanoma and appears to improve physical function while preserving QoL during checkpoint inhibitor therapy.
https://t.co/IxYxw4kDE3

[Karen Steindorf @SteindorfKaren]

Wir bieten @DKFZ:
Promotionsstelle im Bereich Bewegung während/nach einer Krebserkrankung für unser EU-Projekt @PREFERABLE_II. Nähere Infos unter:
https://t.co/SKCRWFDXOv

[Irene Norstedt @IreneNorstedt]

Did you visit #MissionCancer and projects ULTRAPLACAD & @PREFERABLE_II at the #EUOpenDay?

#EUfunded R&I is the Mission’s ally in reaching its objectives:
🎯Improve understanding
🎯Prevention
🎯Cure
🎯QoL

On day 3 of #EWAC2023 discover this #EUMission
👇
https://t.co/C1fC9Tx2sF

[PREFERABLE_II @PREFERABLE_II]

@PREFERABLE_MBC and @PREFERABLE_II partners contributed to the @uncan_eu discussion on priorities for cancer survivorship research.

[UNCAN.eu @uncan_eu]

Javier Carmona @FJCarmonas presented the session of today in which the topics of Pediatric cancer, Cancer and aging and Survivorship will be discussed #UNCAN_eu

[Kathi Apostolidis @kgapo]

Congratulations to the @PREFERABLE_II team for the great work recognised at the #EUOpenDay!
The importance of #physicalactivity for #cancerpatients and #survivors was highlighted this week at the Annual Congress of FAVO @favo_it an ECPC @cancereu member
#EUHealthResearch #HADEA

[PREFERABLE_II @PREFERABLE_II]

The PREFERABLE II project was showcased during the #EUOpenDay! We informed many visitors about the project and measured their handgrip strength, which we often do with pts in our exercise-oncology trials to evaluate exercise effects. #EUCancerMission #EUHealthResearch @EU_HaDEA

[Irene Norstedt @IreneNorstedt]

#EUOpenDay is in full swing! 💃

Happy to see so many visitors interested in our #EUMissions and especially #MissionCancer 💜